Share: Facebook Twitter LinkedIn
Activity Provided By:

Clinical Care Options, LLC.

SGLT2 Inhibitor Therapy in Type 2 Diabetes

Access Activity

Overview / Abstract:

Target Audience

This activity is primarily intended for endocrinologists, primary care physicians, and nurses who care for patients with T2D.

Program Overview

The goal of this activity is to improve learners’ competence and performance in SGLT2 inhibitor treatment decisions for patients with T2D with and without related comorbidities.

Learning Objectives

Upon completion of this activity, participants should be able to:

Apply recommendations from the latest ADA and AACE diabetes management guidelines regarding use of SGLT2-I drugs in patients with varying degrees of CV and/or renal risk
Consider the key clinical evidence from CVOTs with SGLT2-I drugs in management decisions for patients with T2D

Expiration

Dec 09, 2021

Discipline(s)

Nursing CNE, Physician CME

Format

Online

Credits / Hours

0.5 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
Anne Peters, MD
Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
Keck School of Medicine of USC
Los Angeles, California

Sponsors / Supporters / Grant Providers

Boehringer Ingelheim Pharmaceuticals, Inc.

Keywords / Search Terms

Relias LLC FREE CME., Relias LLC. Diabetes Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map